MA41642A - Variants de protoxine ii et méthodes d'utilisation - Google Patents

Variants de protoxine ii et méthodes d'utilisation

Info

Publication number
MA41642A
MA41642A MA041642A MA41642A MA41642A MA 41642 A MA41642 A MA 41642A MA 041642 A MA041642 A MA 041642A MA 41642 A MA41642 A MA 41642A MA 41642 A MA41642 A MA 41642A
Authority
MA
Morocco
Prior art keywords
protoxin
variants
methods
Prior art date
Application number
MA041642A
Other languages
English (en)
Inventor
Mack Flinspach
Alan Wickenden
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA41642A publication Critical patent/MA41642A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA041642A 2015-03-03 2016-02-24 Variants de protoxine ii et méthodes d'utilisation MA41642A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562127339P 2015-03-03 2015-03-03

Publications (1)

Publication Number Publication Date
MA41642A true MA41642A (fr) 2018-01-09

Family

ID=56849056

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041642A MA41642A (fr) 2015-03-03 2016-02-24 Variants de protoxine ii et méthodes d'utilisation

Country Status (15)

Country Link
US (3) US20160257726A1 (fr)
EP (1) EP3265476A4 (fr)
JP (2) JP2018512123A (fr)
KR (1) KR20170120703A (fr)
CN (1) CN107531769A (fr)
AR (1) AR103838A1 (fr)
AU (2) AU2016226443B2 (fr)
BR (1) BR112017018834A2 (fr)
CA (1) CA2978435A1 (fr)
HK (1) HK1249118A1 (fr)
IL (2) IL254273A0 (fr)
MA (1) MA41642A (fr)
MX (1) MX2017011223A (fr)
TW (1) TW201706292A (fr)
WO (1) WO2016140859A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
ES2841173T3 (es) 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
KR20170097020A (ko) 2014-12-23 2017-08-25 오토메드 피티와이 리미티드 딜리버리 장치, 시스템 및 관련 방법
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法
CN109369785B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 Ccotx1毒素及其应用
CN109369784B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 PaTx-1毒素及其应用
US11957542B2 (en) 2020-04-30 2024-04-16 Automed Patent Holdco, Llc Sensing complete injection for animal injection device
CN114957431B (zh) * 2022-06-27 2023-06-20 四川丽妍工坊生物科技有限公司 一种皮肤抗皱多肽Cj2a2、制备方法及应用
CN120699106A (zh) * 2024-03-26 2025-09-26 广州锡滔生物医药科技有限公司 一种多肽及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP1005526B1 (fr) 1997-04-16 2010-10-13 Unigene Laboratories, Inc. Expression directe de peptides dans un milieu de culture
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
EP1348466A3 (fr) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Méthode de traitement du douleur avec adenosine tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP4929288B2 (ja) 2005-11-04 2012-05-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法
WO2007109324A2 (fr) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Bloqueurs puissants et sélectifs du canal sodique nav1.7
BRPI0716228A2 (pt) 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2334315B1 (fr) 2008-09-03 2023-01-18 NoNO Inc. Agents et méthodes de traitement de la douleur
WO2010104115A1 (fr) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 Procédé de préparation d'un polypeptide reconnaissant de façon spécifique une protéine membranaire
CA2774350A1 (fr) 2009-09-15 2011-03-24 Alomone Preclinical Ltd. Nouveaux peptides isoles de venin d'araignee et leurs utilisations
WO2012004664A2 (fr) * 2010-07-07 2012-01-12 Purdue Pharma L.P. Analogues de toxine peptidique de canal sodique
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
CN103492575A (zh) 2011-01-18 2014-01-01 安姆根有限公司 NaV1.7敲除小鼠及其用途
US9102751B2 (en) * 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
CA2873860A1 (fr) 2012-05-18 2013-11-21 Janssen Biotech, Inc. Variants d'huwentoxine iv et procedes d'utilisation
WO2014016673A1 (fr) 2012-07-27 2014-01-30 Purdue Pharma L.P. Peptides de blocage des canaux sodiques et leur utilisation
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
ES2841173T3 (es) * 2013-10-03 2021-07-07 Janssen Biotech Inc Variantes de Protoxina-II y métodos de uso
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法

Also Published As

Publication number Publication date
IL254273A0 (en) 2017-10-31
JP2018512123A (ja) 2018-05-17
IL282482A (en) 2021-06-30
AU2016226443A1 (en) 2017-09-21
WO2016140859A2 (fr) 2016-09-09
TW201706292A (zh) 2017-02-16
US20160257726A1 (en) 2016-09-08
CA2978435A1 (fr) 2016-09-09
BR112017018834A2 (pt) 2018-04-17
WO2016140859A3 (fr) 2016-10-27
AU2021200400A1 (en) 2021-03-18
KR20170120703A (ko) 2017-10-31
US20210363204A1 (en) 2021-11-25
AU2016226443B2 (en) 2020-10-22
JP2022071050A (ja) 2022-05-13
EP3265476A2 (fr) 2018-01-10
EP3265476A4 (fr) 2018-08-22
AR103838A1 (es) 2017-06-07
US20170334959A1 (en) 2017-11-23
CN107531769A (zh) 2018-01-02
US10995125B2 (en) 2021-05-04
MX2017011223A (es) 2018-06-20
HK1249118A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3700527A4 (fr) Inhibiteurs de papd5 et leurs méthodes d'utilisation
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA43284A (fr) Composés et leurs méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation
EP3393382A4 (fr) Couteau ophtalmique et méthodes d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3377612A4 (fr) Expression fonctionnelle de monooxygénases et procédés d'utilisation
EP3373969A4 (fr) Composés interagissant avec le glycane et méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3353328A4 (fr) Modulateurs de l'expression de kras
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA49715A (fr) Oligomères et conjugués d'oligomères
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
EP3386295A4 (fr) Appareil et méthodes d'ostréiculture
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA42118A (fr) Benzamides substitués et leurs méthodes d'utilisation